Analysts See $0.24 EPS for Qualys, Inc. (QLYS); Heat Biologics, Inc. (HTBX) Had 5 Bullish Analysts

April 17, 2018 - By Winifred Garcia

Qualys, Inc. (NASDAQ:QLYS) Logo

Among 5 analysts covering Heat Biologics (NASDAQ:HTBX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heat Biologics had 7 analyst reports since September 1, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, September 3 by H.C. Wainwright. Noble Financial initiated the stock with “Buy” rating in Friday, January 8 report. The firm has “Buy” rating given on Wednesday, June 7 by Noble Financial. The stock of Heat Biologics, Inc. (NASDAQ:HTBX) has “Buy” rating given on Tuesday, September 1 by Cantor Fitzgerald. On Thursday, February 4 the stock rating was downgraded by Cantor Fitzgerald to “Speculative Buy”. Griffin initiated Heat Biologics, Inc. (NASDAQ:HTBX) on Tuesday, September 12 with “Buy” rating. The rating was initiated by Roth Capital on Monday, June 20 with “Buy”. See Heat Biologics, Inc. (NASDAQ:HTBX) latest ratings:

Analysts expect Qualys, Inc. (NASDAQ:QLYS) to report $0.24 EPS on May, 1 after the close.They anticipate $0.32 EPS change or 57.14% from last quarter’s $0.56 EPS. QLYS’s profit would be $9.27M giving it 81.61 P/E if the $0.24 EPS is correct. After having $0.37 EPS previously, Qualys, Inc.’s analysts see -35.14% EPS growth. The stock increased 1.82% or $1.4 during the last trading session, reaching $78.35. About 305,687 shares traded or 2.22% up from the average. Qualys, Inc. (NASDAQ:QLYS) has risen 101.10% since April 17, 2017 and is uptrending. It has outperformed by 89.55% the S&P500.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company has market cap of $6.91 million. The firm develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. It currently has negative earnings. The Company’s product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer.

Investors sentiment increased to 1 in 2017 Q4. Its up 0.50, from 0.5 in 2017Q3. It increased, as 1 investors sold Heat Biologics, Inc. shares while 3 reduced holdings. 1 funds opened positions while 3 raised stakes. 3.62 million shares or 29.05% more from 2.81 million shares in 2017Q3 were reported. Bancorporation Of Ny Mellon stated it has 0% of its portfolio in Heat Biologics, Inc. (NASDAQ:HTBX). Northern has invested 0% in Heat Biologics, Inc. (NASDAQ:HTBX). Royal Bankshares Of Canada reported 0% in Heat Biologics, Inc. (NASDAQ:HTBX). Two Sigma Ltd Liability Corporation has 0% invested in Heat Biologics, Inc. (NASDAQ:HTBX) for 34,685 shares. Morgan Stanley invested in 8,527 shares or 0% of the stock. Sabby Ltd Liability Corp has 0.09% invested in Heat Biologics, Inc. (NASDAQ:HTBX). Blackrock, New York-based fund reported 7,030 shares. Virtu Financial Limited Company owns 41,228 shares or 0% of their US portfolio. Vanguard Group reported 814,565 shares. Franklin Street Advsr Nc, a North Carolina-based fund reported 20,500 shares.

The stock decreased 5.43% or $0.07 during the last trading session, reaching $1.22. About 128,917 shares traded. Heat Biologics, Inc. (NASDAQ:HTBX) has declined 78.52% since April 17, 2017 and is downtrending. It has underperformed by 90.07% the S&P500.

Qualys, Inc. provides cloud-based security and compliance solutions in the United States and internationally. The company has market cap of $3.03 billion. The firm offers Qualys Cloud Suite, which includes Vulnerability Management, Continuous Monitoring, Cloud Agent, AssetView, ThreatPROTECT, Policy Compliance, PCI Compliance, Security Assessment Questionnaire, Web Application Scanning, and Web Application Firewall. It has a 77.57 P/E ratio. The Company’s integrated suite of security and compliance solutions delivered on its Qualys Cloud Platform enables clients to identify their IT assets, collect and analyze IT security data, discover and prioritize vulnerabilities, recommend remediation actions, and verify the implementation of such actions.

Investors sentiment increased to 1.86 in Q4 2017. Its up 0.23, from 1.63 in 2017Q3. It is positive, as 17 investors sold Qualys, Inc. shares while 47 reduced holdings. 53 funds opened positions while 66 raised stakes. 28.48 million shares or 5.40% more from 27.02 million shares in 2017Q3 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0.01% in Qualys, Inc. (NASDAQ:QLYS). Oppenheimer Asset Mgmt accumulated 0.01% or 5,227 shares. Moreover, Guggenheim Ltd Liability Co has 0.01% invested in Qualys, Inc. (NASDAQ:QLYS). Blackrock invested in 0.01% or 3.99 million shares. State Board Of Administration Of Florida Retirement Systems reported 17,515 shares. Amalgamated Savings Bank holds 0.01% or 4,701 shares in its portfolio. Synovus owns 14,365 shares. State Street invested in 0% or 970,672 shares. Pictet Asset Ltd holds 0.1% or 668,500 shares. Lpl Ltd Llc invested in 0% or 3,686 shares. Goldman Sachs Grp Inc Inc invested 0% of its portfolio in Qualys, Inc. (NASDAQ:QLYS). Us-based Champlain Investment Partners Ltd has invested 1.13% in Qualys, Inc. (NASDAQ:QLYS). De Burlo Grp holds 78,000 shares. Renaissance Technologies Ltd Liability holds 0.09% or 1.30 million shares in its portfolio. Moreover, Eulav Asset has 0.02% invested in Qualys, Inc. (NASDAQ:QLYS).

Since December 11, 2017, it had 0 insider buys, and 11 insider sales for $4.27 million activity. 9,801 shares valued at $575,356 were sold by Thakar Sumedh S on Friday, February 9. Shares for $143,690 were sold by Deeba Amer. Another trade for 10,000 shares valued at $718,651 was made by Rogers Kristi Marie on Friday, February 16. POSEY BRUCE K also sold $1.89 million worth of Qualys, Inc. (NASDAQ:QLYS) on Wednesday, February 14.

Qualys, Inc. (NASDAQ:QLYS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Winifred Garcia

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts